Cargando…
Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular Carcinomas
SIMPLE SUMMARY: The response of hepatocellular carcinomas (HCC) to transarterial chemoembolization (TACE) is variable. In view of the dynamic development of treatment options for HCCs, an early selection of the most effective therapy for maximizing individual treatment success has a high medical nee...
Autores principales: | Olbrich, Anne, Gros, Olga, Ebel, Sebastian, Denecke, Timm, Gößmann, Holger, Linder, Nicolas, Lordick, Florian, Forstmeyer, Dirk, Seehofer, Daniel, Sucher, Robert, Rademacher, Sebastian, Niemeyer, Johannes, Matz-Soja, Madlen, Berg, Thomas, van Bömmel, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563450/ https://www.ncbi.nlm.nih.gov/pubmed/36230730 http://dx.doi.org/10.3390/cancers14194807 |
Ejemplares similares
-
Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers
por: Veelken, Rhea, et al.
Publicado: (2021) -
Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan
por: Struck, Manuel Florian, et al.
Publicado: (2023) -
The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment
por: Fischer, Janett, et al.
Publicado: (2022) -
The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab
por: Lieb, Sabine, et al.
Publicado: (2023) -
Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery
por: Struck, Manuel Florian, et al.
Publicado: (2021)